Robert W. Baird Raises Nurix Therapeutics (NASDAQ:NRIX) Price Target to $25.00

Nurix Therapeutics (NASDAQ:NRIX) had its price target increased by research analysts at Robert W. Baird from $24.00 to $25.00 in a report issued on Thursday, Benzinga reports. The firm currently has an “outperform” rating on the stock. Robert W. Baird’s price target points to a potential upside of 49.34% from the stock’s previous close.

A number of other research analysts also recently issued reports on NRIX. Needham & Company LLC restated a “buy” rating and set a $31.00 target price on shares of Nurix Therapeutics in a research report on Tuesday. Royal Bank of Canada cut their price objective on shares of Nurix Therapeutics from $24.00 to $22.00 and set an “outperform” rating for the company in a report on Friday, February 16th. Wells Fargo & Company cut their price objective on shares of Nurix Therapeutics from $23.00 to $20.00 and set an “overweight” rating for the company in a report on Friday, February 16th. Morgan Stanley lifted their price objective on shares of Nurix Therapeutics from $9.00 to $10.00 and gave the company an “equal weight” rating in a report on Monday, February 26th. Finally, HC Wainwright cut their price objective on shares of Nurix Therapeutics from $35.00 to $19.00 and set a “buy” rating for the company in a report on Tuesday, February 20th. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, Nurix Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $21.33.

Nurix Therapeutics Stock Performance

NASDAQ NRIX opened at $16.74 on Thursday. The company has a fifty day moving average of $12.64 and a 200 day moving average of $9.26. Nurix Therapeutics has a 1 year low of $4.22 and a 1 year high of $18.12.

Nurix Therapeutics (NASDAQ:NRIX) last posted its earnings results on Thursday, February 15th. The company reported ($0.77) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.26). The business had revenue of $15.16 million for the quarter, compared to analyst estimates of $30.66 million. Nurix Therapeutics had a negative net margin of 178.93% and a negative return on equity of 67.08%. As a group, analysts predict that Nurix Therapeutics will post -3.26 EPS for the current year.

Insider Transactions at Nurix Therapeutics

In other news, CFO Houte Hans Van sold 6,812 shares of the business’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $10.02, for a total transaction of $68,256.24. Following the completion of the sale, the chief financial officer now owns 68,333 shares of the company’s stock, valued at $684,696.66. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold 10,817 shares of company stock valued at $100,256 over the last 90 days. Corporate insiders own 7.20% of the company’s stock.

Institutional Trading of Nurix Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Charles Schwab Investment Management Inc. grew its stake in Nurix Therapeutics by 48.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 568,576 shares of the company’s stock valued at $4,469,000 after acquiring an additional 184,617 shares in the last quarter. Kennedy Capital Management LLC grew its stake in Nurix Therapeutics by 192.7% during the 3rd quarter. Kennedy Capital Management LLC now owns 163,623 shares of the company’s stock valued at $1,286,000 after acquiring an additional 107,719 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its stake in Nurix Therapeutics by 351.0% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 5,611 shares of the company’s stock valued at $58,000 after acquiring an additional 4,367 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its stake in Nurix Therapeutics by 40.9% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 183,923 shares of the company’s stock valued at $1,446,000 after acquiring an additional 53,429 shares in the last quarter. Finally, ARK Investment Management LLC grew its stake in Nurix Therapeutics by 23.2% during the 4th quarter. ARK Investment Management LLC now owns 3,194,999 shares of the company’s stock valued at $32,972,000 after acquiring an additional 601,952 shares in the last quarter.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.